The molecular biology enzymes, reagents and kits market size is estimated to be USD 18,722.1 million in 2022 and is expected to witness a CAGR of 9.97% during the forecast period 2023-2033. Surge research activities and R&D spending technological developments in life science industry, and increase in number of genome projects are factors contributing to the market growth. Furthermore, increase in omics-based R&D initiatives and continuous development and launches of sequencing reagents & kits by companies are other factors supporting the market growth. However, unfavourable reimbursement policies for genetic testing is expected to hinder the growth.

Increase in omics-based R&D initiatives is expected to propel the market growth during the projected period. Research into the awareness of genomes, proteomes, and transcriptomes has expanded as a result of developments in synthetic biology and the expanding demand for analytical tools. These multi-omics-based research initiatives are the cutting-edge ideas for identifying molecular drugs, and they help scientists to understand the genetic causes of disease and the manner in which it progresses at the cellular level. The need for molecular biotechnology tools including enzymes and other proteins is rising as a result of the increase in omics-based R&D initiatives. For instance, restriction endonucleases have DNA cleavage activity that is sequence-specific and other enzymatic activities that ligate and amplify nucleic acids, which has spurred various different types of molecular biology study.

Continuous development and launches of sequencing reagents & kits by companies is predicted to fuel the market growth during the market growth. Companies are constantly developing and releasing their sequencing reagents and kits in response to the growing demand for sequencing technologies on a worldwide scale. For instance, Jumpcode Genomics introduced the CRISPRclean Single Cell RNA Boost kit in March 2022. By removing uninformative sequences and providing more insightful analyses of the genomic data, the technique improves single-cell studies. Such activities adequately demonstrate the expansion of the market for molecular biology consumables.

Segmentation

By Product

The market is categorized into enzymes and kits & reagents, reverse transcriptase, polymerase, restriction endonuclease, ligase, others. In 2022, the kits & reagents segment accounted for the highest revenue share due to the wide accessibility of these products in the market, innovative research, and ongoing product introductions from top companies. In December 2021, for instance, PerkinElmer announced the release of the NEXTFLEX Variant-Seq SARS-CoV-2 Kit v2 for disease surveillance and improved sequencing throughput and reliability for variant detection. The company then developed this kit, which works with the Illumina platform, increasing its usage even more. Enzymes are expected to experience the fastest increase in the forecast period due to the continued advancement of cloning technology as a standard laboratory process and the expanding field of molecular biology. This has made it possible for the producers and suppliers to offer different nucleic acid manipulation enzymes. Cloning procedures have advanced as a result of the availability of many sources of enzymes such as ligases, polymerases, nucleases, methylases, phosphatases, and topoisomerases for cloning applications.

By Application

The market is categorized into restriction digestion, sequencing, cloning, PCR, epigenetics, synthetic biology, and others. In the global market, the sequencing segment accounted for the largest revenue share in 2022 owing to development of single-cell sequencing and the dominance of NGS. The expansion of this market is driven by the application of NGS for genomic analysis, cancer diagnosis, and biomarker identification. Major corporations are implementing various business strategies to lead the segment. For instance, Pacific Biosciences and Berry Genomics collaborated together in January 2022 to introduce their long-read sequencing technology to the Chinese clinical market. In the near future, it is projected that activities such as these will propel the segment. The PCR market is anticipated to expand at a constant rate in the upcoming years. As PCR tests established the gold standard for COVID-19 detection, an exponential rise in COVID-19 cases led to an increase in the production of real-time PCR (RT-PCR) based detection kits. Genetic material detection has becoming more widely used due to its precision and reliability. The introduction of new technologies, such as ddPCR (droplet digital PCR), also provides improved detection platforms. It is projected that these developments and the growing number of PCR applications will continue to drive revenue in this market.

By End User

The market is segmented into hospital & diagnostics, academic & research, pharma & biotech, and others. In 2022, the pharma & biotech segment accounted for the largest revenue share owing to fact that the molecular biology tools that streamline workflow, including PCR, sequencing, genotyping, and DNA/RNA extraction enzymes, are widely accepted. The pharma and biotech companies’ use of these products during the development of drug candidates, personalized medical, or diagnostics facilitates product improvements, which in turn boosts sales. The market will be driven in the next years by companies’ extensive use of molecular technologies during R&D and clinical trials. In 2022, the academic and research segment had a large share. The demand for kits and reagents in research institutions increased due to the rise in demand for new diagnostic tools and treatment options for COVID-19 infection. Additionally, the widespread use of PCR and NGS accelerates the development of numerous research projects focusing on the development of health, including cancer, pathogenesis, and mutation. Government funding programmes for these institutions are also helping the industry expand as a result of the rising use of molecular biology supplies.

Regional Markets

In 2022, North America region accounted for the highest revenue in the molecular biology enzymes, reagents and kits market and is expected to maintain its dominance during the forecast period. This is attributed to the existence of well-established companies, renowned research institutes, combined government and private financing, developed healthcare environments, and ease of adoption of new technology. The prevalence of chronic diseases across all age groups and the incidence of cancer in the population are driving up research efforts for prevention and treatment methods. As a result, the need for molecular products is increasing. Asia Pacific is anticipated to witness productive growth during the projection period. Poor healthcare systems, a large population, rising demand for targeted therapeutics, and rapid economic expansion have all given molecular biology companies lucrative growth prospects. Additionally, the greater purchasing power in these countries has spurred western companies to introduce new products and expand their market dominance in these regions, which has raised market revenue.

Competitor Insights

Some of the key players operating in the molecular biology enzymes, reagents and kits market are QIAGEN, Takara Bio, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., New England Biolabs, Merck KGaA, Illumina, Inc., Agilent Technologies, Inc., Promega Corporation, Thermo Fisher Scientific, Inc., and LGC Limited.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Singular Genomics and Agilent Technologies collaborated together to integrate Agilent’s SureSelect Target Enrichment Reagents with Singular’s G4 sequencing platform in February 2022. Both companies’ consumer bases are expanded by the project, which also improves the sequencing options.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product, application, and end user from 2023 to 2033.

Report Scope:

Segmentation: Molecular Biology Enzymes, Reagents and Kits Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Enzymes
• Kits & Reagents
• Reverse Transcriptase
• Polymerase
• Restriction Endonuclease
• Ligase
• Others

Application (Revenue, USD Million), 2022 – 2033

• Restriction Digestion
• Sequencing
• Cloning
• PCR
• Epigenetics
• Synthetic Biology
• Others

End user (Revenue, USD Million), 2022 – 2033

• Hospital & Diagnostics
• Academic & Research
• Pharma & Biotech
• Others

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA